Germany

The acquisition complements BioNTech’s existing capabilities in mRNA design, delivery, and manufacturing, and will integrate CureVac’s advanced research and manufacturing site in Tübingen, Germany.

By acquiring full rights to VVD-214, Vividion is expanding its portfolio of investigational therapies designed to address cancers and immune disorders with high unmet medical needs.

Developed in collaboration with two leading pharmaceutical partners, SynTiso aims to address some of the most pressing challenges facing drug manufacturers today.

This new agreement builds on a multi-year partnership between BioNTech and the UK government that began in January 2023.

This year’s event attracted a record-breaking attendance of over 350 participants, including customers, partners, innovators, and industry leaders from around the world.

Under the agreement, the two companies will initially launch four development programs focused on creating small molecule therapies that target specific GPCRs, including the GLP-1, GIP, and glucagon receptors.

Syntegon’s order intake rose by 11% to €1.8 billion (US$1.9 billion), while revenues increased 7% to €1.6 billion (US$$1.7 billion).

Unlike traditional MRI scanners that require about 1,000 liters of liquid helium and a quench pipe for emergency venting, this system uses only 0.7 liters of helium, owing to its DryCool technology.

Merck KGaA already has a robust presence in oncology, with its top-selling product in 2024 being Erbitux (cetuximab), which brought in about US$1.25 billion.